News

People with Parkinson’s disease who have clinically significant anxiety tend to walk more slowly and with shorter steps than people with the disease who don’t have anxiety. That’s according to the study, “The impact of anxiety on gait impairments in Parkinson’s disease: insights from sensor-based gait analysis,” which…

Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…

Tiny bubbles containing a flaky form of phosphorus, called black phosphorus, delivered to the brain may help to control overactive microglia — the brain’s resident immune cells — that drive the inflammation damaging to nerve cells in Parkinson’s disease, scientists in China report. In a study in a rat…

There were more cases of Parkinson’s disease and cancer than expected among attorneys who worked near a now-closed dry cleaner in Rochester, New York that leaked trichloroethylene (TCE) and other dry cleaning solvents into the soil, a study finds. While they failed to reach statistical significance, the findings add…

Deficits in emotional processing, rather than impaired ability to simulate facial expressions, likely explain problems Parkinson’s disease patients encounter when trying to recognize emotions on human faces, a study suggests. Researchers asked patients and healthy individuals to recognize different, non-emotional facial expressions on avatars, either static or moving. No…

A Phase 1 clinical trial testing the investigational stem cell-based therapy STEM-PD in people with Parkinson’s disease has advanced to a higher dose following positive findings about the safety of the lower dose, according to a press release from Lund University. Four patients will receive the high dose…

Irlab Therapeutics is preparing to start a Phase 1 clinical trial of IRL757, its oral tablet candidate to ease apathy in Parkinson’s disease and other neurological conditions. The trial, which follows its approval by the Swedish Medical Products Agency, is fully financed by a 20 million SEK (about…

NKGen Biotech plans to begin clinical testing of SNK01, a natural killer (NK) cell therapy being developed to treat neurodegenerative diseases, in people with Parkinson’s disease, the company announced. This follows a go-ahead by the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application…

Scientists at the Fraunhofer Institute for Applied Information Technology (FIT) in Germany are collaborating on a project with the aim of creating a digital platform and application that, used with a wearable device, can track the course of Parkinson’s disease and potentially improve patients’ quality of life. Called…

Potential environmentally-driven alterations in certain epigenetic marks — DNA modifications that control gene activity — were detected in the blood of people with newly diagnosed, treatment-naïve, sporadic Parkinson’s disease, a study revealed. These epigenetic marks were linked with cellular processes driving ongoing neurodegeneration that underlies Parkinson’s, and changed over…